Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab
Table 1
Baseline characteristics of the study population.
(100%)
Sex
Male
5 (29%)
Median age in years (range)
63.4 (42-85)
Demographics
Education
Low (junior high school)
5 (29%)
Intermediate (senior high school)
7 (41%)
High (graduate bachelor or master)
5 (29%)
Work situation
Work
6 (35%)
Sick leave
3 (18%)
Retired
8 (47%)
Marital status
Married/cohabitation with partner
12 (71%)
Divorced/separated
2 (12%)
Widowed
2 (12%)
Single/never married
1 (6%)
Children
Young children (0-21 yrs)
5 (29%)
Adult children (≥21 yrs)
10 (59%)
No children
2 (12%)
Psychiatric history
Depression
1 (6%)
No psychiatric history
15 (88%)
Psychotropic treatment
Antidepressant
2 (12%)
Hypnotic benzodiazepine
3 (18%)
ECOG performance status
0
7 (41%)
1
5 (29%)
2
5 (29%)
Treatment
Previous treatment before ipilimumab
Chemotherapy
9 (53%)
BRAF/MEK inhibitors
1 (6%)
Study drug (IFN or TriMixDC-MEL)
7 (41%)
Radiotherapy
9 (53%) non-CNS, 1 (6%) CNS
Surgery
2 (12%)
Therapy during ipilimumab treatment
Radiotherapy
2 (12%)
Surgery
2 (12%)
Retreatment with ipilimumab after interruption
3 (18%)
Dose of ipilumumab per administration
3 mg/kg
8 (47%)
10 mg/kg
9 (53%)
Survival
Number of patients disease-free and without any cancer treatment at baseline
17 (100%)
Median time since starting ipilimumab at baseline in years (range)
5.6 (2.1-9.3)
Median time since stopping ipilimumab at baseline in years (range)
4.0 (1.9–8.6)
Median time since complete remission or best overall response at baseline in years (range)
4.0 (1.6–8.6)
Number of patients who completed the 1-year follow-up assessment
15 (88%)
Melanoma
Median time to diagnosis of stages IIIC-IV in years (range)
6.8 (3.4-12.1)
Location of primary tumor
Head
3 (18%)
Neck
1 (6%)
Trunk
4 (24%)
Upper extremity
2 (12%)
Lower extremity
4 (24%)
Unknown
3 (18%)
AJCC TNM stage 8th edition
IIIC
2 (12%)
IV-M1a
1 (6%)
IV-M1b
7 (41%)
IV-M1c
6 (35%)
IV-M1d
1 (6%)
One survivor obtained a complete metabolic response on 18F-FDG/PET and a partial response on CT scan; 1 survivor obtained a stable disease both on 18F-FDG/PET and CT scan; 15 survivors obtained a complete response, defined as the absence of any abnormality on whole-body 18F-FDG PET/CT.
